<SEC-DOCUMENT>0001193125-23-001510.txt : 20230104
<SEC-HEADER>0001193125-23-001510.hdr.sgml : 20230104
<ACCEPTANCE-DATETIME>20230104162108
ACCESSION NUMBER:		0001193125-23-001510
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230104
DATE AS OF CHANGE:		20230104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		23506740

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		206-337-1030

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d389002d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20230103" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_NoTradingSymbolFlag_duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember" name="dei:NoTradingSymbolFlag" contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">true</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2023-01-03_to_2023-01-03" name="dei:EntityCentralIndexKey" contextRef="duration_2023-01-03_to_2023-01-03">0001937653</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2023-01-03_to_2023-01-03" name="dei:AmendmentFlag" contextRef="duration_2023-01-03_to_2023-01-03">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="zyme-20230103.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-01-03_to_2023-01-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-03</xbrli:startDate> <xbrli:endDate>2023-01-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-03</xbrli:startDate> <xbrli:endDate>2023-01-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-03</xbrli:startDate> <xbrli:endDate>2023-01-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-01-03_to_2023-01-03">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-01-03_to_2023-01-03" format="ixt:date-monthname-day-year-en">January&#160;3, 2023</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityRegistrantName">Zymeworks Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityFileNumber">001-41535</ix:nonNumeric></span>&#32;<br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityTaxIdentificationNumber">88-3099146</ix:nonNumeric></span>&#32;<br /></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityAddressAddressLine1">108 Patriot Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityAddressAddressLine2">Suite A</ix:nonNumeric><br /><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityAddressCityOrTown">Middletown</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityAddressPostalZipCode">19709</ix:nonNumeric><br /></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:CityAreaCode">302</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:LocalPhoneNumber">274-8744</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:Security12bTitle">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:TradingSymbol">ZYME</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember" name="dei:Security12bTitle">Preferred Stock Purchase Rights</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style=" -sec-ix-hidden:Hidden_dei_NoTradingSymbolFlag_duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">N/A</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="duration_2023-01-03_to_2023-01-03" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;2.02 Results of Operations and Financial Condition.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;4, 2023, Zymeworks Inc. (the &#8220;Company&#8221;) announced certain information relating to the Company&#8217;s financial condition as of December&#160;31, 2022, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable debt securities, of approximately $490&#160;million, which excludes the expected zanidatamab-related reimbursements for R&amp;D expenses in the fourth quarter of approximately $30&#160;million. The Company also announced that it expects such cash resources to fund the Company&#8217;s current planned operations through at least the end of 2026 (such information, the &#8220;Financial Condition Information&#8221;). The Financial Condition Information is set forth in a press release issued by the Company on January&#160;4, 2023 under the caption &#8220;Updated Financial Guidance&#8221;. The preliminary and unaudited estimate of cash resources is based on management&#8217;s initial analysis of operations for the quarter and year ended December&#160;31, 2022 and is subject to further internal review and audit by the Company&#8217;s external auditors. A copy of this press release is attached hereto as Exhibit 99.1.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release is incorporated herein by reference, except for the Financial Condition Information, which information is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such filing.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;3, 2023, the Company removed Dr.&#160;Neil Josephson from the position of Chief Medical Officer, effective immediately.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01 Other Events.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;4, 2023, the Company issued a press release announcing a corporate update on its strategic priorities and other matters. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference, except for the Financial Condition Information, which information is furnished as described under Item 2.02 above.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;contains</span> certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. Forward-looking statements are identified by such words as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate&#8221; and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company&#8217;s plans, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the Company&#8217;s preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable debt securities, and the Company&#8217;s anticipated funding of its current operations and related expected timelines. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d389002dex991.htm">Press Release dated January&#160;4, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded as Inline XBRL document).</td></tr></table> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style=" text-align: center;margin:auto; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-weight:bold">ZYMEWORKS INC.</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: January&#160;4, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"><span style="font-style:italic">/s/ Neil Klompas</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Neil Klompas</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Operating Officer</td></tr></table> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3</p></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d389002dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g389002g0104123941708.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Provides updated key priorities and focus on enterprise value framework </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation
initiatives originally planned for 2022</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Announces additional financial guidance on expected cash runway; provides unaudited cash and cash resources
balance as of December</I><I></I><I>&nbsp;31, 2022</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Announces recommended Phase 2 dose (RP2D) for zanidatamab zovodotin (ZW49) </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vancouver, British Columbia (January 04, 2023)</B> &#150; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,
multifunctional biotherapeutics, today announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Since becoming Chair and CEO a year ago, the Company has made tremendous progress with a renewed focus on priority R&amp;D programs and improved
operational execution. During 2022, we advanced our two ongoing pivotal clinical studies of zanidatamab, presented important new data for both zanidatamab and zanidatamab zovodotin (formerly ZW49) to inform additional clinical development
opportunities, advanced our preclinical product pipeline towards two new Investigational New Drug applications (INDs) planned for 2024, and gained further insights from our legacy platform licenses with our pharmaceutical partners as they advance
product candidates into and through clinical development,&#148; stated Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Through a
series of financial initiatives successfully executed during 2022, including the Jazz collaboration that closed in the fourth quarter, we were able to transform our financial position to ensure adequate funding of our planned operations over the
next several years as we continue to build a broad and exciting product pipeline comprised of both antibody-drug conjugates (ADCs) and multispecific antibody therapeutics.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key 2022 Accomplishments: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fully recruited the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01</FONT></FONT> (<U>NCT04466891</U>) pivotal clinical study for zanidatamab before <FONT STYLE="white-space:nowrap">mid-2022</FONT> and announced <U>positive topline
data</U> before the end of 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recruitment of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-GEA-01</FONT></FONT>
(<U>NCT05152147</U>) pivotal clinical study for zanidatamab is well under way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Through a series of publications and presentations, outlined additional data from ongoing clinical studies
supporting the potential for further development efforts for zanidatamab beyond biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Presented Phase 1 clinical study data</U> for zanidatamab zovodotin and outlined the future clinical
development path; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selected and advanced two new preclinical product candidates (ZW191 and ZW171), that leverage Zymeworks&#146;
novel, therapeutic technology platforms, with planned Investigational New Drug (IND) applications for both candidates in 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presented an overview of our future scientific strategy to build an innovative and differentiated product
pipeline focused on next-generation ADCs and multispecific antibody therapeutics as a part of our <U>early Research and Development day</U> in October 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completed commercialization partnership arrangements for zanidatamab with closing of the <U>Jazz collaboration
agreement</U> in the fourth quarter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Completed redomicile to Delaware</U> and a stock exchange listing change from the New York Stock Exchange
(NYSE) to The Nasdaq Stock Market LLC (Nasdaq), better aligning Zymeworks with U.S. shareholder base and peer companies in the biotechnology sector; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completed a <U>new equity financing</U> in January 2022 at a price per common share of $8.00 resulting in gross
proceeds of $115&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2022 was an important year for Zymeworks and its shareholders,&#148; said Mr.&nbsp;Galbraith.
&#147;With the key accomplishments of 2022, we are able to look forward to the future as we aim to make substantial progress in 2023 and 2024 across all five of the key focus areas of our enterprise value framework.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Updated Financial Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks provided an update
on its unaudited cash resources, which consist of cash, cash equivalents, and marketable debt securities. As of December&nbsp;31, 2022, we had cash resources on hand of approximately $490&nbsp;million (unaudited), which excludes the expected
zanidatamab-related reimbursements pursuant to our agreement with Jazz for R&amp;D expenses incurred in the fourth quarter of approximately $30&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fourth quarter of 2022, we received gross proceeds of $375&nbsp;million pursuant to the collaboration agreement with Jazz. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a substantially improved financial position and reduced cash burn rate, we are providing additional financial guidance to allow for an improved
understanding of our future planned spending. Based on current operating plans, we expect a net operating cash burn of between $90&nbsp;million and $120&nbsp;million for calendar year 2023, including planned capital expenditures of approximately
$15&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on current operating plans, we expect to have cash resources to fund research and development programs, as well as operations,
through at least the end of 2026, and potentially beyond. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Throughout the course of 2022, we worked diligently to improve our financial situation.
Today, we are pleased to share that we have cash resources that should support our ongoing development plans over the next several years,&#148; said Chris Astle, Ph.D., SVP and Chief Financial Officer at Zymeworks. &#147;We now have the balance
sheet strength to both fund our current operating plans and be opportunistic in evaluating additional R&amp;D opportunities internally and externally, while maintaining a strong financial position. We will continue to be financially disciplined in
order to ensure that future spending is prioritized and allocated in those areas expected to drive increases in enterprise value.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key 2023 and 2024 Priorities and Zymeworks&#146; Enterprise Value Framework </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;With a significantly improved financial position, Zymeworks is now well positioned to build upon our key priorities and enhance shareholder value through
focusing on the five key areas of our enterprise value framework,&#148; said Neil Klompas, President and Chief Operating Officer at Zymeworks. &#147;As we look forward, we will be focused on delivering substantial progress across the five key areas
of: our zanidatamab collaborations with Jazz and BeiGene, our early R&amp;D programs, further development of zanidatamab zovodotin and our portfolio of legacy platform licensing agreements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zanidatamab Collaboration with Jazz Pharmaceuticals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreement with Jazz represents an important component of our commercialization strategy for zanidatamab and our financial strategy for
expanding our product pipeline. To date, we have received $375&nbsp;million in proceeds from the Jazz collaboration and are eligible for reimbursement for ongoing zanidatamab-related costs expended after October&nbsp;19, 2022. We remain eligible to
receive regulatory approval milestones of up to $525&nbsp;million, commercial milestones of up to $862.5&nbsp;million, and royalties of between 10% and 20% of future zanidatamab sales, pending regulatory approval of zanidatamab. During 2023, we
expect to report additional clinical data from our ongoing Phase 2 study in front-line GEA at the ASCO GI symposium on January 19th in San Francisco and the full data set from our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01</FONT></FONT> pivotal clinical trial at a major medical meeting in the first half of 2023. In conjunction with Jazz, we look forward to providing updates on progress
towards regulatory filings, new clinical studies, and future clinical data releases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zanidatamab Collaboration with BeiGene </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our collaboration agreements with BeiGene in the key Asia Pacific (APAC) regions (excluding Japan) are important given the high prevalence of BTC and GEA in
the APAC region. To date, we have received approximately $60&nbsp;million in upfront payments and milestone payments from the BeiGene collaboration as well as certain <FONT STYLE="white-space:nowrap">co-development</FONT> funding for zanidatamab
clinical studies. Through our collaboration with BeiGene on zanidatamab and zanidatamab zovodotin, we remain eligible to receive up to $390&nbsp;million in additional development and commercial milestones together with tiered royalties of up to 20%
of future product sales, pending regulatory approval. In conjunction with BeiGene, we look forward to providing updates on progress towards regulatory filings in the APAC region, new clinical studies, and future clinical data releases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Early Development Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
current scientific strategy provides for a broad and differentiated product pipeline of ADCs and multispecific antibody therapeutics to be developed from our technology platforms with the goal of five new INDs by 2027. We expect to submit INDs for
our lead preclinical programs (ZW191 and ZW171) in 2024. During 2023, we expect to nominate an additional product candidate for preclinical development with an expected IND filing in 2025. We plan to continue actively presenting and publishing
additional data on our preclinical programs in 2023, with a focus on the AACR meeting scheduled for the second quarter. We expect to evaluate and complete additional multi-product collaborations and partnerships in 2023 and 2024 to expand the
breadth of our research and early development programs. We plan to make additional investments during 2023 and 2024 in the size and capabilities of our research group in order to enable the desired speed, quality, diversity, and novelty in our
future product pipeline. Further, we also plan to evaluate external opportunities in adjacent research areas to expand our focus beyond the current technology platforms. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zanidatamab Zovodotin (ZW49) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today, we announced that we will continue to develop zanidatamab zovodotin using a dose of 2.5 mg/kg every three weeks (Q3W), and in the next year expect to
present additional data from our Phase 1 clinical study that support this RP2D. Since the presentation of our Phase 1 data at the European Society of Medical Oncology (ESMO) conference in September 2022, we have continued to enroll subjects in our
ongoing Phase 1 study to gather further data for zanidatamab zovodotin monotherapy treated at the RP2D. During 2023, we expect to evaluate zanidatamab zovodotin, as monotherapy and/or in combination with the current respective standards of care, in
four different patient cohorts: (i)&nbsp;HER2-amplified <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), (ii) HER2-expressing ovarian and endometrial cancers, (iii)&nbsp;HER2-positive GEA, and (iv)&nbsp;HER2-amplified
colorectal cancer. We also expect to commence enrollment in studies evaluating zanidatamab zovodotin in two different cohorts: (i)&nbsp;in patients with HER2-positive breast cancer after progression on <FONT STYLE="white-space:nowrap">T-Dxd,</FONT>
and (ii)&nbsp;in patients with <FONT STYLE="white-space:nowrap">HER2-low</FONT> breast cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These study cohorts will be undertaken with a planned
expansion of clinical study sites in North and South America, Europe, and Asia Pacific regions. Based on our development efforts to date, we believe that zanidatamab zovodotin represents a unique and differentiated product candidate among the HER2
ADCs currently under active development. We anticipate the results of these planned clinical studies may provide the rationale for one or more registrational studies of zanidatamab zovodotin, which we would expect to undertake with a future
collaboration partner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legacy Platform Licensing Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continue to have active licensing arrangements with nine key pharmaceutical and biotechnology partners, with four product candidates currently in clinical
development. To date, we have received approximately $180&nbsp;million in upfront and milestone payments from these arrangements, excluding amounts received related to zanidatamab or zanidatamab zovodotin. During 2023 and 2024, we expect to earn
additional milestone payments under our existing agreements as products continue to advance in development as well as the potential for payments for expansion or extension of existing agreements. We continue to evaluate the feasibility of
monetization of all or a portion of our rights to receive future milestone payments and royalties under these legacy agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Changes
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to ensure appropriate focus on both supporting the further development and commercialization of zanidatamab with our partners, Jazz and
BeiGene, as well as the expansion of our early-stage product pipeline, the Company will be <FONT STYLE="white-space:nowrap">re-organizing</FONT> its current development group into two separate groups: one focused on zanidatamab and one focused on
the remainder of the product portfolio, including zanidatamab zovodotin. In conjunction with the internal <FONT STYLE="white-space:nowrap">re-organization,</FONT> Dr.&nbsp;Neil Josephson, will be leaving the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The late-stage development group will focus on supporting the further clinical development and
commercialization of zanidatamab by our partners in their respective regions. Based in our current Seattle operational site, the late-stage development group will be led by the current development management team, reporting to Neil Klompas,
President and COO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The early-stage development group will be focused on the clinical development of zanidatamab zovodotin, ZW171, ZW191, and future
product candidates. In order to ensure timely development with a global perspective, the early-stage development group will be regionally focused among new operational sites to cover the Americas (California), Europe and MENA (Dublin) and
Asia-Pacific (Singapore). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the late-stage development group, the Company&#146;s Seattle site will retain responsibilities for global
technical and manufacturing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The early-stage development group will be led by newly appointed SVP, Early-Stage Development, Dr.&nbsp;Jeffrey
Smith, to be based in the Company&#146;s Dublin offices. Dr.&nbsp;Smith has more than thirty years of drug development experience working for pharmaceutical, biotechnology and contract research organizations in Europe and North America. He was
formerly the <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Medical Officer of Alder BioPharmaceuticals, based in Seattle, which was acquired by Lundbeck in 2019 for approximately $2&nbsp;billion. Dr.&nbsp;Smith has an M.D. from the
University of London. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company announced the promotions of Mark Hollywood to Executive Vice President and Head of Technical and
Manufacturing Operations, and Daniel Dex to General Counsel and Corporate Secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I wish to thank Dr.&nbsp;Josephson for his efforts and
contributions as Chief Medical Officer during my first year as CEO of Zymeworks. I would like to welcome Jeff to the organization and congratulate both Mark and Daniel on well-earned promotions within my leadership team,&#148; stated
Mr.&nbsp;Galbraith. &#147;I am confident that this new organizational structure will ensure we can properly support our partners&#146; efforts on the timely commercialization of zanidatamab while also improving the speed of development of our
growing product pipeline.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics.
Zymeworks&#146; mission is to make a meaningful difference for people impacted by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers and other diseases. Zymeworks&#146; complementary
therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks&#146; proprietary Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal
clinical trials as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for patients with HER2-expressing cancers. Zymeworks&#146; next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks&#146; proprietary Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> and ZymeLink<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience
and capabilities in both ADC and multispecific antibody therapeutics (MSAT). In addition to Zymeworks&#146; wholly-owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical
companies. For information about Zymeworks, visit <U>www.zymeworks.com</U> and follow <U>@ZymeworksInc</U> on Twitter. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#147;forward-looking statements&#148; or information within the meaning of the applicable securities legislation, including
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to
Zymeworks&#146; expectations regarding implementation of its strategic priorities, including those with respect to its pipeline and R&amp;D strategy; preliminary and unaudited estimates of its cash, cash equivalents, and marketable debt securities;
Zymeworks&#146; anticipated financial runway and funding of its current operations; Zymeworks&#146; anticipated cash burn; Zymeworks&#146; estimated reimbursements from collaboration partners; future financial position; timing of milestones with
respect to zanidatamab, ZW49 and other potential product candidates; potential therapeutic effects and commercial potential of zanidatamab and Zymeworks&#146; other product candidates; the anticipated benefits of the collaboration agreement with
Jazz; the anticipated benefits of Zymeworks&#146; agreements with BeiGene and its other collaborators; Zymeworks&#146; ability to receive additional payments pursuant to the collaboration agreement, including any future milestone payments and
royalties; the commercial potential of zanidatamab and Zymeworks&#146; and Jazz&#146;s ability to obtain regulatory approval of and successfully commercialize zanidatamab; the anticipated internal
<FONT STYLE="white-space:nowrap">re-organization</FONT> and the expected timing and benefits thereof; the timing of and results of the interactions with regulators, including anticipated regulatory filings and the timing thereof; current and future
partnerships and strategic collaborations; Zymeworks&#146; clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future clinical trials and studies and presentation of related
data; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as &#147;believe&#148;, &#147;future&#148;, &#147;anticipate&#148;,
&#147;approximately&#148;, &#147;will&#148;, &#147;plans&#148;, &#147;may&#148;, &#147;potential&#148;, &#147;expect&#148;, &#147;should&#148;, &#147;continue&#148;, and similar expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All
forward-looking statements are based upon Zymeworks&#146; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its
expectations, and its beliefs may not prove correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actual results could differ materially from those described or implied by such forward-looking
statements as a result of various factors, including, without limitation: Zymeworks&#146; assumptions regarding its financial condition may be incorrect; any of Zymeworks&#146; or its partners&#146; product candidates may fail in development, may
not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional
requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Zymeworks&#146; business, research and
clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#146; behalf, may be more severe and more prolonged than currently
anticipated; clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#146; or its collaborators&#146; product candidates; Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations; and the
factors described under &#147;Risk Factors&#148; in Zymeworks&#146; quarterly and annual reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for its quarter
ended September&nbsp;30, 2022 (a copy of which may be obtained at www.sec.gov and <U>www.sedar.com</U>). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, we are in the process of finalizing our financial results for the fourth quarter and fiscal
year 2022, and therefore our finalized and audited results and final analysis of those results are not yet available. The preliminary expectations regarding <FONT STYLE="white-space:nowrap">year-end</FONT> cash, cash equivalents, and marketable debt
securities are the responsibility of management, are subject to management&#146;s review and actual results could differ from management&#146;s expectations. The actual results are also subject to audit by our independent registered public
accounting firm and no assurance is given by our independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December&nbsp;31,
2022, based on the foregoing estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they
will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be
required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor inquiries: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack Spinks </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@zymeworks.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604)
<FONT STYLE="white-space:nowrap">678-1388</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@zymeworks.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zyme-20230103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/4/2023 2:22:30 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:zyme="http://www.zymeworks.com/20230103"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:us-types="http://fasb.org/us-types/2022"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.zymeworks.com/20230103"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20230103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20230103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20230103_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="zyme_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="zyme_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>zyme-20230103_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/4/2023 2:22:32 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20230103.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="zyme-20230103.xsd#zyme_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="zyme-20230103.xsd#zyme_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightsMember" xlink:type="locator" xlink:label="us-gaap_RightsMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="zyme_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RightsMember" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="43.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="47.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>zyme-20230103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/4/2023 2:22:30 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Trading Symbol Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="zyme-20230103.xsd#zyme_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="zyme_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="zyme-20230103.xsd#zyme_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="zyme_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, par value $0.00001 per share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, par value $0.00001 per share [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightsMember" xlink:type="locator" xlink:label="us-gaap_RightsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightsMember" xlink:to="us-gaap_RightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Purchase Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Purchase Rights [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>zyme-20230103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 71.0.4 -->
<!-- Creation date: 1/4/2023 2:22:30 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20230103.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="zyme-20230103.xsd#zyme_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="zyme_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="zyme-20230103.xsd#zyme_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="zyme_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightsMember" xlink:type="locator" xlink:label="us-gaap_RightsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RightsMember" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g389002g0104123941708.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389002g0104123941708.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I .D# 2(  A$! Q$!_\0
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MJ@UMIH&D1W7VE--M5FSG>(QFM&OKL5C?;1Y4K&>&P?L9<S=PHHHK@.X****
M"BBB@ HHHH **** "DI:2@!:*8\T46/,D1,]-S 4S[7;?\_$7_?8J7**W8$U
M%1+<P,<+-&3C/#"E2XAD;:DT;'T# T<T>X$E%(2%!+$ #J34:W$#G"S1L>N
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M.V*FG\/Z>D>_P]XCF34%(,:O>[E;U!%16^K^ 9K=)+^RMK>[*CS8FMF&UN_
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@ 4444 %%%% !1110 4444 %%%% !1110 4E+24 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140700853423440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zyme_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.00001 per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zyme_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember', window );">Preferred Stock Purchase Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zyme_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Stock Purchase Rights<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zyme_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zyme_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zyme_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d389002d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20230103.xsd" xlink:type="simple"/>
    <context id="duration_2023-01-03_to_2023-01-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <dei:NoTradingSymbolFlag
      contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember"
      id="Hidden_dei_NoTradingSymbolFlag_duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">true</dei:NoTradingSymbolFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-01-03_to_2023-01-03"
      id="Hidden_dei_EntityCentralIndexKey_duration_2023-01-03_to_2023-01-03">0001937653</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="duration_2023-01-03_to_2023-01-03"
      id="Hidden_dei_AmendmentFlag_duration_2023-01-03_to_2023-01-03">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="duration_2023-01-03_to_2023-01-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-01-03_to_2023-01-03">2023-01-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-01-03_to_2023-01-03">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-01-03_to_2023-01-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-01-03_to_2023-01-03">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-01-03_to_2023-01-03">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-01-03_to_2023-01-03">108 Patriot Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-01-03_to_2023-01-03">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-01-03_to_2023-01-03">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-01-03_to_2023-01-03">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-01-03_to_2023-01-03">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-01-03_to_2023-01-03">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-01-03_to_2023-01-03">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-01-03_to_2023-01-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-01-03_to_2023-01-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-01-03_to_2023-01-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-01-03_to_2023-01-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">Preferred Stock Purchase Rights</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="duration_2023-01-03_to_2023-01-03_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-01-03_to_2023-01-03">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( **")%8D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "B@B1699!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ HH(D5@E&AA_M    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ HH(D5IE<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "B@B168VVBA^0$   A%@  &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ HH(D5I^@&_"Q
M @  X@P   T              ( !)@T  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "B@B16EXJ[',     3 @  "P              @ $"$   7W)E;',O
M+G)E;'-02P$"% ,4    " "B@B16'#AEZC\!   \ @  #P
M@ 'K$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ HH(D5B0>FZ*M
M^ $  !H              ( !5Q(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ HH(D5F60>9(9 0  SP,  !,              ( !
M/!,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  AA0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d389002d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d389002d8k.htm">d389002d8k.htm</File>
    <File>d389002dex991.htm</File>
    <File>zyme-20230103.xsd</File>
    <File>zyme-20230103_def.xml</File>
    <File>zyme-20230103_lab.xml</File>
    <File>zyme-20230103_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d389002d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "zyme-20230103_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d389002d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20230103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20230103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "zyme-20230103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 31,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20230103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d389002d8k.htm",
      "contextRef": "duration_2023-01-03_to_2023-01-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d389002d8k.htm",
      "contextRef": "duration_2023-01-03_to_2023-01-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.00001 per share [Member]",
        "terseLabel": "Common Stock, par value $0.00001 per share [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Purchase Rights [Member]",
        "terseLabel": "Preferred Stock Purchase Rights [Member]"
       }
      }
     },
     "localname": "RightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "zyme_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.zymeworks.com/20230103",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "zyme_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.zymeworks.com/20230103",
     "presentation": [
      "http://www.zymeworks.com//20230103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-23-001510-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-001510-xbrl.zip
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M6Y$P]KBB \]7*0)B>GB<9#+*!,Q9X 5T-+"UTQ(CX427,!8"%Y4 /F$.RV)
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M5CN+ N:'U:/!QS-L5A617@T(XP_4/*/0N1\QORYJU$<L*A*0CZC>_H UITX
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MWO$EQD^CZQMO:H--]SH912R!Y_Q.+HU9.2Y9U/.;4.F\]9T<8&R2,$B);F"
M?[O1+[B'#!S].ZQ?N),/^NO=?[NV$.8 S%Q!>Q'"<85YIJ?M.K?Q$:L2MFQ.
M)\GY*.88V#SBRCGT@Z8JZ$WB:UJ+<8V"PI>)=8NN/3D[_Y(:-[7-R+.N$Z5Q
M!U+3I]2]Z#BDG.I*URDKD&P1>Z59+ADU.B47N&V1:D)>!*KH]9]VQ+#H>&@\
M5G9T'B:BQ!H9+A!WD8A&%>*N,4IN 6)=7H-Z13;N4:]^WR6VQ$EW)XGC[+M
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M(F3Y(G_>6=_#_=YTV \X+6QW*!N.NQDTPZ&<'?X.7WZX_'BR]S]02P,$%
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M*,68FJ:V>2?/+!1WW&<WYQ3;<GY&P3SA/Z3,JL7598JO_P)02P,$%     @
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MS)\]LR/FS?QU49?\"U!+ 0(4 Q0    ( *.")%;_??9%B1,  *Y\   .
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M92TR,#(S,#$P,U]L86(N>&UL4$L! A0#%     @ HX(D5AF3V8!X!0  &3L
M !4              ( ! TH  'IY;64M,C R,S Q,#-?<')E+GAM;%!+!08
1    !@ & (,!  "N3P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
